Clovis Oncology Germany GmbH
Pharmaceutical Companies · München
Clovis Oncology Germany GmbH is a pharmaceutical company based in München, Bavaria, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Clovis Oncology Germany GmbH Address & Contact
Company profile
2011
Founded
Clovis Oncology Germany GmbH Overview
Clovis Oncology Germany GmbH is the former German branch of the American Clovis Oncology, Inc., a pharmaceutical company specializing in oncology based in Boulder, Colorado. *Clovis Oncology, Inc. was founded in 2011 and specialized in PARP inhibitors for the treatment of ovarian cancer.* The company has made significant contributions in research and development in the field of innovative oncology and has a wide influence in the pharmaceutical industry. Its headquarters in Munich, Bavaria, is situated in a regional center for biomedical research and pharmaceutical innovations that is home to numerous renowned universities and research institutions.
Field of Activity & Products
Clovis Oncology was known for Rubraca (Rucaparib), a PARP inhibitor (Poly(ADP-Ribose) Polymerase inhibitor) for the treatment of recurrent, BRCA-mutated ovarian cancer and castration-resistant prostate cancer. *Rubraca was approved in Europe and Germany via the EMA and was used in cancer treatment as a monotherapy and maintenance therapy.* Additionally, the company continued to research further therapeutic approaches to combat solid tumors, underscoring its strategic focus on innovative oncology drugs. This research extended not only to PARP inhibitors but also to other immunotherapy approaches that have gained more attention in recent years.
History & Regulation
Clovis Oncology, Inc. was founded in 2011 and listed on NASDAQ. *The company filed for Chapter 11 bankruptcy in December 2022 after Rubraca lost market share in competition with other PARP inhibitors (Olaparib, Niraparib).* The indirect consequences of this bankruptcy affected not only Clovis employees but also patients and healthcare professionals who depended on the company's innovative therapies. As part of the bankruptcy proceedings, all commercial activities were halted. The remaining activities of Clovis Oncology Germany GmbH in Germany were managed within the framework of the insolvency process, marking a significant setback in the company's role in the German market, where there is a growing demand for oncology therapies.
A central aspect of pharmaceutical regulation in Germany and Europe, especially through the EMA (European Medicines Agency), concerns the strict approval procedures for new drugs and therapies. Clovis Oncology had to adhere to this regulatory framework to successfully position itself in the European market. The Phase-3 studies conducted for Rucaparib were challenging from both a medical and regulatory perspective to demonstrate the safety and efficacy of the therapy. These processes highlight the importance of consistently maintaining high standards in research, development, and clinical trials.
Regional Significance and Characteristics
The regional significance of Clovis Oncology in Bavaria can be seen not only through its headquarters in Munich but also through its networking with important institutions in the field of biomedical research and clinical studies. Bavaria is considered one of the leading locations for the pharmaceutical industry in Germany, with access to professionals, innovative ideas, and a strong infrastructure.
Distinctive features of Clovis Oncology include its specialization in PARP inhibitors and its focus on genetically determined cancers. This niche strategy allowed the company to position itself as a significant player in the fight against specific types of cancer, such as BRCA-mutated ovarian cancer.
In summary, Clovis Oncology Germany GmbH, despite the challenges of recent years, has had a significant impact on the field of oncology and could also play a role in the discussion of innovative cancer treatments in the future, provided that new research findings and therapeutic approaches are developed.
Further information: Pharmaceutical companies in Bavaria or all pharmaceutical companies in Germany on Sanoliste.
```Frequently asked questions about Clovis Oncology Germany GmbH
What does Clovis Oncology Germany GmbH do?
Clovis Oncology Germany GmbH is a pharmaceutical company based in München that develops, manufactures or distributes pharmaceutical products. The company is active in the German healthcare market.
Where is Clovis Oncology Germany GmbH located?
Clovis Oncology Germany GmbH is headquartered in München, Germany. More information can be found on the company's website.
What products does Clovis Oncology Germany GmbH distribute?
Clovis Oncology Germany GmbH is active in the pharmaceutical sector. Detailed information on the products offered and therapeutic areas can be found on the company's website or via the contact details provided.
More Pharmaceutical Companies in München
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.